Advaxis, Inc.
www.advaxis.comAdvaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Read more
Advaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Read more
Country
State
New Jersey
City (Headquarters)
Princeton
Industry
Founded
2002
Estimated Revenue
$5,000,000 to $10,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
President and Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Executive Director
Email ****** @****.comPhone (***) ****-****Chairman Scientific Advisory Board
Email ****** @****.comPhone (***) ****-****Senior Director , Global Clinical Ops and Program Management
Email ****** @****.comPhone (***) ****-****
Technologies
(1)
We'll help you understand if Lusha can solve your business needs.
